TrueLab TrueLab Care
Evidence reviews · DOI-cited sources · research use only
Research 05 Nov 2026 · 3 min read · 3 sources

CJC-1295 vs ipamorelin: two receptors compared side by side

These two are almost always discussed as a pair, and unusually the pairing has a real basis, they act through different receptors, so combining them is a coherent design rather than doubling up. But one of them has a naming problem serious enough that the trial data people quote may not describe the material they are holding.

TL

TrueLab Research Team

Reviewed 05 Nov 2026 · Summarises peer-reviewed literature · Not medical advice

Key takeaways

  • They are not alternatives to each other. CJC-1295 is a GHRH analogue; ipamorelin is a ghrelin-receptor agonist[^3].
  • Growth hormone release is under two-sided control, so the two act on genuinely separate inputs, which is the honest basis for the 'stack' logic.
  • The name CJC-1295 originally described a molecule carrying a DAC group that binds albumin covalently[^1]. The material sold as 'no DAC' is a different compound.
  • The published human data on prolonged GH elevation describes the DAC version[^2], quoting it for the no-DAC material is a category error.
  • Ipamorelin's selectivity is its documented feature: it acts through the GHRP-like receptor rather than the GHRH receptor[^3].

Most compound comparisons in this field turn out to be a choice between two ways of doing the same thing. This one does not, and that is what makes it worth writing down.

They act on different inputs

Growth hormone release from the anterior pituitary is under two-sided control. Growth hormone-releasing hormone drives it, somatostatin restrains it, and a third input, the ghrelin receptor, formally the GH secretagogue receptor, amplifies it.

Two doors into the same room

Why these compounds complement rather than duplicate

CJC-1295, GHRH analogue

  • Built from hGRF(1-29), the shortest fragment retaining full activity
  • Substitutions resist dipeptidyl peptidase-IV cleavage[1]
  • Acts at the GHRH receptor

Ipamorelin, ghrelin-receptor agonist

  • Pentapeptide: Aib-His-D-2-Nal-D-Phe-Lys-NH₂
  • From the GHRP-1 series
  • Profiling showed it acts through the GHRP-like receptor, not GHRH[3]

CJC-1295 works on the first. Ipamorelin works on the third. Pharmacological profiling with GHRP and GHRH antagonists established that ipamorelin acts through the GHRP-like receptor and not the GHRH receptor3.

So they are complementary rather than redundant. That is the honest basis of the stack logic, and equally the reason that an experiment confounding the two mechanisms produces results nobody can interpret. We set this out at more length in the growth-hormone secretagogue article.

The naming problem, stated plainly

This is the part to get right before citing anything.

The original CJC-1295 described by Jetté and colleagues carries an added maleimidopropionamide group on a lysine, designed to form a covalent bond in vivo with the free thiol on Cys34 of serum albumin1. That bioconjugation is the molecule's reason for existing: it converts a peptide with a very short half-life into a long-acting one. The same principle, in its non-covalent form, is the subject of the fatty acid trick.

Where the citation goes wrong

The single most important thing to check before quoting anything about CJC-1295

Original CJC-1295 carries DAC

A maleimidopropionamide group on lysine, designed to bond covalently with Cys34 of serum albumin[1]

That bond is the entire point

It converts a very short half-life into a long-acting one, the reason the compound was interesting

Human data describes THAT molecule

Prolonged GH and IGF-I elevation was measured with the DAC version[2]

'No DAC' is a different compound

Same peptide backbone, no albumin conjugation, no prolonged action, so the trial data does not transfer

The human study people quote, prolonged elevation of GH and IGF-I in healthy adults2, was conducted with that version.

Material sold as "CJC-1295 no DAC" is the peptide backbone without the conjugating group. Same sequence, different molecule, different pharmacokinetics. Citing the DAC trial data as though it described the no-DAC material is not a small imprecision; it attributes to one compound the single property the other was engineered to have.

Our product page for CJC-1295 no DAC carries this caveat in the physicochemical card for exactly this reason.

Ipamorelin's actual claim to interest

Ipamorelin's documented feature is selectivity, and it is worth being precise about what that means here.

Earlier growth hormone secretagogues released GH but also moved cortisol and prolactin. Ipamorelin was characterised as the first selective one, releasing GH without the accompanying hormonal noise3. That is a comparative statement against its own predecessors, and it is the kind of selectivity claim that the piece on reading selectivity says to check: named comparator, stated direction, measured in one system.

The unnatural residues in the sequence, Aib, D-2-Nal, D-Phe, are protease resistance built into the chain, the strategy described in decoding a peptide name.

Which to choose

The framing "which is better" does not apply, because they are not substitutes.

If the question is about GHRH-receptor signalling, CJC-1295 is the relevant tool, with the DAC caveat determining which literature applies to which material. If the question is about the ghrelin receptor and selective GH release, ipamorelin is, and its own 1998 characterisation is the reference.

If the question is about the combination, then the two-receptor architecture is precisely the point, and any experiment needs to be designed so the two contributions can be told apart afterwards. Running both and attributing the result to "the stack" answers nothing about either.

What this means in the vial

The handling differences are modest. Ipamorelin is a pentapeptide of 711.9 g/mol; the CJC-1295 no DAC backbone is a 29-residue chain of about 3647 g/mol.

The smaller peptide dissolves readily; the longer one behaves like other chains of that size, and the guidance in when the powder will not dissolve applies. Both carry the same requirement that applies to everything in this catalogue: the certificate tells you what the material is, and the name on the vial, as this compound demonstrates better than any other here, does not always tell you which molecule you have.

References

  1. 1. Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology 2005 ; 146(7):3052-3058 doi:10.1210/en.2004-1286 ↩
  2. 2. Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism 2006 ; 91(3):799-805 doi:10.1210/jc.2005-1536 ↩
  3. 3. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology 1998 ; 139(5):552-561 doi:10.1530/eje.0.1390552 ↩

This article summarises published research for educational purposes. It is not medical advice and does not describe permitted uses of any product. Compounds discussed are supplied strictly for in-vitro laboratory research and are not for human or animal consumption.

Continue reading

All The Science →